D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $34.00 price target on the stock.

NRXP has been the topic of a number of other reports. Ascendiant Capital Markets upped their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a report on Monday, April 27th. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, April 27th. BTIG Research restated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Finally, Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.25.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP traded up $0.04 on Tuesday, reaching $3.04. The company had a trading volume of 1,329,956 shares, compared to its average volume of 1,062,989. The firm has a market capitalization of $100.53 million, a PE ratio of -2.19 and a beta of 2.02. The firm has a 50-day moving average of $2.22 and a 200-day moving average of $2.32. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.28. The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $7.53 million. As a group, sell-side analysts expect that NRx Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Anson Funds Management LP increased its stake in NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $994,000. Bleakley Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $318,000. AdvisorShares Investments LLC increased its position in shares of NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after acquiring an additional 92,463 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the period. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.